You’re grasping at straws, gofish. Baraclude’s addition to the AASLD guidelines in Feb 2007 was deemed sufficiently consequential that BMY mentioned it explicitly in its 8-K filing with the SEC dated 4/26/07:
There is no mention in any SEC filing of Baraclude’s endorsement by the group you cited: the National AIDS Treatment Advocacy Group. Nor should there be because NATAP does not have anywhere near the same standing as AASLD in the hepatitis arena.
The fact is: it took Baraclude two years to get included in the AASLD guidelines for HBV because these guidelines tend to a trailing indicator of the acceptance of a new drug by leading specialists. Tyzeka will very likely be included in the AASLD guidelines within the same relative time frame that it took for Baraclude to get included.
To reiterate, you claimed in msg #1387 that Tyzeka is deficient and dead in the water because it is not yet included in the AASLD guidelines. I’m saying that your assertion is BS.
Market Data 
Markets 
AI
